
|Videos|December 18, 2018
Benefit With Cemiplimab in Patients With mCSCC
Author(s)Danny Rischin, MD, MBBS, FRACP
Danny Rischin, MD, MBBS, FRACP, shares his insights on cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.
Advertisement
Danny Rischin, MD, MBBS, FRACP, director, division of cancer medicine, and head, department of medical oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, shares his insights on cemiplimab (Libtayo) as a treatment for patients with metastatic cutaneous squamous cell carcinoma (mCSCC).
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































